Literature DB >> 21317715

ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma.

Markku Miettinen1, Zeng-Feng Wang, Anders Paetau, Shyh-Han Tan, Albert Dobi, Shiv Srivastava, Isabell Sesterhenn.   

Abstract

ERG, an ETS family transcription factor, is known to be expressed in endothelial cells, and oncogenic ERG gene fusions occur in subsets of prostatic carcinoma, acute myeloid leukemia, and Ewing sarcoma. In this study, we immunohistochemically investigated nuclear ERG expression using a new monoclonal antibody, CPDR ERG-MAb, that is highly specific for detecting ERG protein and ERG-expressing prostate carcinomas. A broad range of vascular endothelial (n = 250), other mesenchymal (n = 973), and epithelial tumors (n = 657) was examined to determine the use of ERG immunohistochemistry in surgical pathology. Only immunostains with ERG-positive normal endothelia (internal control) were considered valid, and only nuclear staining was considered to be positive. In adult tissues, ERG was restricted to endothelial cells and to a subset of bone marrow precursors, but early fetal mesenchyme and subpopulations of fetal cartilage were also positive. In vascular tumors, ERG was expressed in endothelia of all hemangiomas and lymphangiomas, and typically extensively expressed in 96 of 100 angiosarcomas, 42 of 43 epithelioid hemangioendotheliomas, and all 26 Kaposi sarcomas. Among nonvascular mesenchymal tumors, only blastic extramedullary myeloid tumors (7 of 10) and rare Ewing sarcomas (2 of 29) were positive. Among epithelial tumors, 30 of 66 prostatic adenocarcinomas showed focal-to-extensive ERG positivity, with no immunoreactivity in the normal prostate. Other carcinomas and epithelial tumors (n = 643) were ERG negative, with the exception of 1 of 42 large cell undifferentiated pulmonary carcinomas and 1 of 27 mesotheliomas, each of which showed focal nuclear ERG positivity. On the basis of the above observations, ERG is a highly specific new marker for benign and malignant vascular tumors. Among epithelial tumors, ERG shows a great promise as a marker to identify prostatic carcinoma in both primary and metastatic settings.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21317715      PMCID: PMC6880747          DOI: 10.1097/PAS.0b013e318206b67b

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  31 in total

Review 1.  Role of ETS family transcription factors in vascular development and angiogenesis.

Authors:  Y Sato
Journal:  Cell Struct Funct       Date:  2001-02       Impact factor: 2.212

2.  Expression of Fli-1, a nuclear transcription factor, distinguishes vascular neoplasms from potential mimics.

Authors:  A L Folpe; E M Chand; J R Goldblum; S W Weiss
Journal:  Am J Surg Pathol       Date:  2001-08       Impact factor: 6.394

3.  CD31 expression in intratumoral macrophages: a potential diagnostic pitfall.

Authors:  J K McKenney; S W Weiss; A L Folpe
Journal:  Am J Surg Pathol       Date:  2001-09       Impact factor: 6.394

4.  Cellular hemangiomas ("hemangioendotheliomas") in infants. Light microscopic, immunohistochemical, and ultrastructural observations.

Authors:  F Gonzalez-Crussi; M Reyes-Mugica
Journal:  Am J Surg Pathol       Date:  1991-08       Impact factor: 6.394

5.  Antibody-based detection of ERG rearrangement-positive prostate cancer.

Authors:  Kyung Park; Scott A Tomlins; Kumaran M Mudaliar; Ya-Lin Chiu; Raquel Esgueva; Rohit Mehra; Khalid Suleman; Sooryanarayana Varambally; John C Brenner; Theresa MacDonald; Abhishek Srivastava; Ashutosh K Tewari; Ubaradka Sathyanarayana; Dea Nagy; Gary Pestano; Lakshmi P Kunju; Francesca Demichelis; Arul M Chinnaiyan; Mark A Rubin
Journal:  Neoplasia       Date:  2010-07       Impact factor: 5.715

6.  Consistent detection of TLS/FUS-ERG chimeric transcripts in acute myeloid leukemia with t(16;21)(p11;q22) and identification of a novel transcript.

Authors:  X T Kong; K Ida; H Ichikawa; K Shimizu; M Ohki; N Maseki; Y Kaneko; M Sako; Y Kobayashi; A Tojou; I Miura; H Kakuda; T Funabiki; K Horibe; H Hamaguchi; Y Akiyama; F Bessho; M Yanagisawa; Y Hayashi
Journal:  Blood       Date:  1997-08-01       Impact factor: 22.113

7.  Distribution of keratins in normal endothelial cells and a spectrum of vascular tumors: implications in tumor diagnosis.

Authors:  M Miettinen; J F Fetsch
Journal:  Hum Pathol       Date:  2000-09       Impact factor: 3.466

8.  Utility of the immunohistochemical detection of FLI-1 expression in round cell and vascular neoplasm using a monoclonal antibody.

Authors:  Sabrina Rossi; Enrico Orvieto; Alberto Furlanetto; Licia Laurino; Vito Ninfo; Angelo P Dei Tos
Journal:  Mod Pathol       Date:  2004-05       Impact factor: 7.842

9.  Heterogeneity of vascular endothelial cells with relevance to diagnosis of vascular tumours.

Authors:  I Kuzu; R Bicknell; A L Harris; M Jones; K C Gatter; D Y Mason
Journal:  J Clin Pathol       Date:  1992-02       Impact factor: 3.411

10.  The transcription factor Erg is essential for definitive hematopoiesis and the function of adult hematopoietic stem cells.

Authors:  Stephen J Loughran; Elizabeth A Kruse; Douglas F Hacking; Carolyn A de Graaf; Craig D Hyland; Tracy A Willson; Katya J Henley; Sarah Ellis; Anne K Voss; Donald Metcalf; Douglas J Hilton; Warren S Alexander; Benjamin T Kile
Journal:  Nat Immunol       Date:  2008-05-25       Impact factor: 25.606

View more
  67 in total

Review 1.  [Value of core needle biopsy in preoperative diagnostics of soft tissue tumors: possibilities and limitations].

Authors:  A Agaimy
Journal:  Pathologe       Date:  2014-11       Impact factor: 1.011

2.  Vascular endothelial growth factor receptor 2 as a marker for malignant vascular tumors and mesothelioma: an immunohistochemical study of 262 vascular endothelial and 1640 nonvascular tumors.

Authors:  Markku Miettinen; Maarit-Sarlomo Rikala; Janusz Rys; Jerzy Lasota; Zeng-Feng Wang
Journal:  Am J Surg Pathol       Date:  2012-04       Impact factor: 6.394

3.  Claudin-5 as an immunohistochemical marker for angiosarcoma and hemangioendotheliomas.

Authors:  Markku Miettinen; Maarit Sarlomo-Rikala; Zeng-Feng Wang
Journal:  Am J Surg Pathol       Date:  2011-12       Impact factor: 6.394

4.  Prox1 transcription factor as a marker for vascular tumors-evaluation of 314 vascular endothelial and 1086 nonvascular tumors.

Authors:  Markku Miettinen; Zeng-Feng Wang
Journal:  Am J Surg Pathol       Date:  2012-03       Impact factor: 6.394

5.  Primary High-Grade Poorly Differentiated Angiosarcoma of an Intra-parotid Lymph Node.

Authors:  Eugenia Ducharne-Asuaje; Dominique Dorion; Louis Lamarre; Jean Michel Coindre; Sameh Geha
Journal:  Head Neck Pathol       Date:  2015-05-01

6.  High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer.

Authors:  Adrian Box; Mohammed Alshalalfa; Samar A Hegazy; Bryan Donnelly; Tarek A Bismar
Journal:  Tumour Biol       Date:  2016-06-07

7.  Pseudomyogenic (epithelioid sarcoma-like) hemangioendothelioma: characterization of five cases.

Authors:  M Fernanda Amary; Paul O'Donnell; Fitim Berisha; Roberto Tirabosco; Tim Briggs; Rob Pollock; Adrienne M Flanagan
Journal:  Skeletal Radiol       Date:  2013-02-05       Impact factor: 2.199

8.  Chinese and Western prostate cancers show alternate pathogenetic pathways in association with ERG status.

Authors:  Liyan Xue; Xueying Mao; Guoping Ren; Elzbieta Stankiewicz; Sakunthala C Kudahetti; Dongmei Lin; Luis Beltran; Daniel M Berney; Yong-Jie Lu
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

9.  CD30 expression in malignant vascular tumors and its diagnostic and clinical implications: a study of 146 cases.

Authors:  Meghna Alimchandani; Zeng-Feng Wang; Markku Miettinen
Journal:  Appl Immunohistochem Mol Morphol       Date:  2014 May-Jun

10.  ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer.

Authors:  J R Gsponer; M Braun; V J Scheble; T Zellweger; A Bachmann; S Perner; T Vlajnic; M Srivastava; S H Tan; A Dobi; I A Sesterhenn; S Srivastava; L Bubendorf; C Ruiz
Journal:  Prostate Cancer Prostatic Dis       Date:  2014-01-28       Impact factor: 5.554

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.